Axsome Therapeutics (NASDAQ:AXSM) Reaches New 52-Week High at $40.25

Share on StockTwits

Axsome Therapeutics Inc (NASDAQ:AXSM)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $40.25 and last traded at $39.12, with a volume of 2114 shares traded. The stock had previously closed at $39.37.

Several equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, October 17th. ValuEngine downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. BidaskClub upgraded shares of Axsome Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $55.00 price target (up previously from $45.00) on shares of Axsome Therapeutics in a report on Tuesday. Finally, Guggenheim initiated coverage on shares of Axsome Therapeutics in a report on Wednesday, October 16th. They issued a “buy” rating and a $48.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $37.63.

The company has a debt-to-equity ratio of 2.80, a current ratio of 2.39 and a quick ratio of 2.39. The firm has a market capitalization of $1.36 billion, a PE ratio of -39.66 and a beta of 2.84. The company has a 50-day moving average price of $27.72 and a 200-day moving average price of $25.21.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.15). On average, research analysts predict that Axsome Therapeutics Inc will post -1.7 earnings per share for the current fiscal year.

In other news, CFO Nick Pizzie bought 2,180 shares of Axsome Therapeutics stock in a transaction on Thursday, September 26th. The shares were bought at an average cost of $24.80 per share, for a total transaction of $54,064.00. Following the acquisition, the chief financial officer now owns 40,440 shares in the company, valued at $1,002,912. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.50% of the stock is currently owned by corporate insiders.

Several institutional investors have recently modified their holdings of AXSM. BlackRock Inc. boosted its holdings in shares of Axsome Therapeutics by 263.1% during the second quarter. BlackRock Inc. now owns 1,690,522 shares of the company’s stock worth $43,531,000 after purchasing an additional 1,224,935 shares during the last quarter. VHCP Management III LLC grew its position in shares of Axsome Therapeutics by 50.9% in the second quarter. VHCP Management III LLC now owns 1,611,329 shares of the company’s stock valued at $41,492,000 after purchasing an additional 543,285 shares during the period. Vanguard Group Inc. grew its position in shares of Axsome Therapeutics by 27.8% in the second quarter. Vanguard Group Inc. now owns 1,152,285 shares of the company’s stock valued at $29,671,000 after purchasing an additional 250,498 shares during the period. VHCP Management II LLC increased its stake in Axsome Therapeutics by 56.1% in the second quarter. VHCP Management II LLC now owns 892,946 shares of the company’s stock valued at $22,993,000 after purchasing an additional 320,990 shares during the last quarter. Finally, State Street Corp increased its stake in Axsome Therapeutics by 12.0% in the third quarter. State Street Corp now owns 729,682 shares of the company’s stock valued at $14,769,000 after purchasing an additional 78,209 shares during the last quarter. 54.64% of the stock is currently owned by institutional investors.

Axsome Therapeutics Company Profile (NASDAQ:AXSM)

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

Recommended Story: Mutual Funds

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.